2 weeks Ago By Defense World Staff
TriSalus Life Sciences ( NASDAQ:TLSI – Get Free Report ) will be posting its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect TriSalus Life Sciences to post earnings of ($0.37) per share for the quarter.
Parties that are interested in participating in the company’s conference call can do so using this link . TriSalus Life Sciences ( NASDAQ:TLSI – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.
21) EPS for the quarter. The firm had revenue of $7.36 million during the quarter.
On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year. TriSalus Life Sciences Price Performance NASDAQ TLSI opened at $4.16 on Thursday.
The company has a fifty day moving average price of $4.46 and a 200-day moving average price of $6.05.
The firm has a market cap of $121.93 million, a price-to-earnings ratio of -1.66 and a beta of 0.
49. TriSalus Life Sciences has a 1 year low of $3.32 and a 1 year high of $10.
42. Insider Buying and Selling at TriSalus Life Sciences Analyst Upgrades and Downgrades Several equities research analysts have recently issued reports on TLSI shares. Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday, October 25th.
They set an “outperform” rating and a $12.50 target price for the company. Oppenheimer assumed coverage on TriSalus Life Sciences in a research note on Monday, September 16th.
They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th.
Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences presently has an average rating of “Buy” and a consensus price target of $12.
50. Get Our Latest Analysis on TriSalus Life Sciences TriSalus Life Sciences Company Profile ( Get Free Report ) TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Read More Five stocks we like better than TriSalus Life Sciences What is a Dividend King? What a Trump Win Looks Like for the Market Now and Into 2025 3 Must-Buy Warren Buffett Stocks for Volatile Times Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop Why is the Ex-Dividend Date Significant to Investors? Macro Headwinds Send Microchip Technology Stock to the Buy Zone Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter ..
